Trial Profile
A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2022
Price :
$35
*
At a glance
- Drugs Timbetasin (Primary)
- Indications Epidermolysis bullosa; Epidermolysis bullosa dystrophica
- Focus Therapeutic Use
- Acronyms CELEB
- Sponsors G-treeBNT; Lenus Therapeutics
- 18 Aug 2022 Status changed from recruiting to discontinued.
- 17 Sep 2021 Planned End Date changed from 1 Aug 2020 to 1 Jun 2022.
- 17 Sep 2021 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2021.